Metagenomi Therapeutics, Inc. (MGX) stock
MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.56−0.05 (-7.95%)
Close on Nov 20, 2026Market cap $21.34MP/E –Yield –
Metagenomi Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Metagenomi Therapeutics's revenue for the twelve months ending Mar 31, 2026 was $22.33M, down 50.7% year over year. For fiscal 2025 it was $25.21M, down 51.8% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.21M | -51.8% |
| FY2024 | Dec 31, 2024 | $52.30M | +16.8% |
| FY2023 | Dec 31, 2023 | $44.76M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | $1.25M | -69.8% |
| Q4 FY2025 | Dec 31, 2025 | $3.91M | -59.3% |
| Q3 FY2025 | Sep 30, 2025 | $8.66M | -24.8% |
| Q2 FY2025 | Jun 30, 2025 | $8.51M | -57.5% |
| Q1 FY2025 | Mar 31, 2025 | $4.13M | -63.0% |
| Q4 FY2024 | Dec 31, 2024 | $9.61M | -22.5% |
| Q3 FY2024 | Sep 30, 2024 | $11.51M | -6.9% |
| Q2 FY2024 | Jun 30, 2024 | $20.01M | +76.5% |
| Q1 FY2024 | Mar 31, 2024 | $11.16M | +28.9% |
| Q4 FY2023 | Dec 31, 2023 | $12.40M | – |
| Q3 FY2023 | Sep 30, 2023 | $12.36M | – |
| Q2 FY2023 | Jun 30, 2023 | $11.34M | – |
| Q1 FY2023 | Mar 31, 2023 | $8.66M | – |
See a number that looks wrong?